An open-label, single-arm, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of the ATR inhibitor SC0245 in advanced solid ...

GLP-1 receptor agonists were not associated with recurrence or progression in well differentiated thyroid cancer, supporting ...

Adults with differentiated thyroid cancer who are using a GLP-1 for the treatment of diabetes or obesity do not have increased risk for cancer recurrence or progression vs. those not using a GLP-1, ...

A new study has shown that overall and cause-specific mortality rates in individuals in the U.S. with low-risk differentiated thyroid cancer (DTC) are low. The study is published in the peer-reviewed ...

A recent phase 3 trial found that 5-year recurrence-free survival was similar among patients who did and did not receive postoperative radioiodine, indicating the treatment can be safely avoided in ...

Graphical Abstract. Relative survival with and without radioiodine therapy (RAI) in intermediate risk papillary thyroid cancer (PTC) and low risk, minimally invasive follicular thyroid cancer (FTC). A ...

Please provide your email address to receive an email when new articles are posted on . Of 155 young patients diagnosed with differentiated thyroid cancer, 52.3% had excellent response to treatment.

Postoperative radioiodine (RAI) versus no radiodine therapy for patients with low-risk differentiated thyroid cancer: A systematic review and meta-analysis. Survival outcomes in radioactive ...

The leading, peer-reviewed resource for original articles, patient-focused reports, and translational research on thyroid cancer and all thyroid related diseases. These revised guidelines begin with ...

Two prospective trials of immunotherapy in thyroid cancer, one of them negative, provided support for precision-medicine approaches that include immunotherapy. The studies were reported simultaneously ...